Welcome to our dedicated page for Aurora Cannabis news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis stock.
Aurora Cannabis Inc. (ACB) is a Canada-based global medical cannabis company with shares listed on NASDAQ and the Toronto Stock Exchange. From an investor and industry perspective, Aurora’s news flow centers on medical cannabis expansion, scientific research, international market development and operational performance.
Company announcements frequently highlight growth in global medical cannabis revenue, leadership positions in key markets, and updates on its plant propagation business through Bevo Farms Ltd. Earnings releases and financial updates provide detail on segment performance across medical cannabis, consumer cannabis and plant propagation, along with adjusted gross margins, adjusted EBITDA and working capital trends.
News items also cover Aurora’s international initiatives, such as investments in its EU-GMP manufacturing facility in Leuna, Germany, launches of proprietary medical flower cultivars in Poland under the Cannabis flos Aurora brand, and the introduction of the Daily Special medical brand in Germany. In Australia, updates include distribution partnerships through MedReleaf Australia and Leafio, aimed at expanding access to Aurora’s medical cannabis products via pharmacy networks.
Scientific and educational developments are another recurring theme. Aurora reports progress in powdery mildew resistance research (PM2) conducted at its Aurora Coast R&D facility, including breeding programs and production trials. The company also announces collaborations like the Physician Experience Platform (PEP) with Copeia, which provides anonymized, peer-reviewed medical cannabis case studies for physicians in multiple countries.
Investors following ACB news can expect coverage of quarterly results, international facility investments, product launches, distribution agreements, conference participation and medical education initiatives. Bookmark this page to monitor how Aurora’s strategic focus on global medical cannabis, science and international markets is reflected in its ongoing news and disclosures.
Aurora (NASDAQ: ACB) will participate in the TD Cowen 46th Annual Health Care Conference on March 2, 2026. CFO Simona King will join a fireside chat and investor meetings to discuss international leadership and manufacturing trends in medical cannabis.
Webcast registration is available on the company's Investor Info page and a replay will be accessible for approximately 90 days. The company also announced completion of the previously disclosed Bevo transaction dated February 4, 2026.
Aurora (NASDAQ: ACB) will ring the Nasdaq closing bell on Wednesday, February 18, 2026 at Nasdaq MarketSite in Times Square. The ceremony begins with a live broadcast at 3:45 p.m. ET and the bell will ring at 4:00 p.m. ET.
CEO and Executive Chairman Miguel Martin will lead the event alongside board and executive representatives to highlight Aurora's medical-first, global cannabis strategy and progress in international markets.
Aurora (NASDAQ: ACB) is expanding its medical cannabis portfolio in Australia and New Zealand, launching multiple THC flower products in New Zealand and four resin cartridges in Australia on Feb 11, 2026. Products use Aurora proprietary genetics and are manufactured at EU‑GMP and TGA‑GMP certified facilities in Canada.
The New Zealand roll‑out includes Big Wave, Night Ride, and Half Moon (Q1 FY27). Australia debuts Chemango Kush, Cosmic Cream, Lunar Express and Soul Train Haze, reinforcing the company’s regional growth focus.
Aurora Cannabis (NASDAQ: ACB) reported Q3 FY2026 results for the quarter ended December 31, 2025. Total net revenue rose 7% YoY to $94.2M, led by a record global medical cannabis revenue of $76.2M (+12%). Adjusted EBITDA was $18.5M, adjusted net income $7.2M, and free cash flow $15.5M. The company holds $154.4M of cash and short-term investments and says its cannabis business is debt-free aside from a $62M non-recourse Bevo Farms liability. Management reaffirmed FY2026 guidance for medical revenue of $269M–$281M and FY adjusted EBITDA of $52M–$57M.
Aurora Cannabis (NASDAQ: ACB) filed a prospectus supplement on February 4, 2026 establishing an at-the-market offering (ATM) program to issue up to U.S.$100 million of common shares from treasury. Proceeds are intended for strategic, accretive uses, including increased cultivation capacity and M&A.
Sales will occur via at-the-market distributions on NASDAQ or other U.S. marketplaces and may include privately negotiated transactions; no sales will be made on Canadian stock exchanges. The ATM is governed by a sales agreement with TD Securities (USA) LLC and the prospectus supplement and registration statement are filed in Canada (except Quebec) and with the SEC.
Aurora (NASDAQ: ACB) launched four new, localized European websites on Feb 3, 2026 to support key medical markets and a central hub at auroramedicine.com.
The sites target Germany, the UK and Poland in native languages, spotlight Canadian and local manufacturing, emphasize science-backed quality and provide resources for healthcare professionals, partners and prospective employees to strengthen regional engagement.
Aurora Cannabis (NASDAQ: ACB) will host a conference call to discuss third quarter 2026 results on Wednesday, February 4, 2026 at 8:00 a.m. Eastern Time (6:00 a.m. Mountain). The company will release Q3 2026 financial results before market open the same day.
Miguel Martin, Executive Chairman and CEO, and Simona King, CFO, will host the call and Q&A. A live webcast link is posted under the company’s Investor Info > Events page at https://www.auroramj.com/investors/.
Aurora Cannabis (NASDAQ: ACB) announced it has been granted Community Plant Variety Rights by the EU Community Plant Variety Office for two proprietary Cannabis sativa L varieties: SOT20R07-007 (Farm Gas™) and ACB21T044 (Sourdough™) on Jan 20, 2026.
The varieties were bred in Canada and are described as high-potency, aromatic, consistent cultivars available to medical patients in Germany, Poland, UK, Canada, and Australia. The EU rights provide exclusive commercial control across the 27 EU member states for the protection period and strengthen Aurora's global genetics portfolio.
Aurora (NASDAQ: ACB) reported significant progress in its powdery mildew (PM) resistance research, nearly one year after discovering a novel genetic resistance source called PM2. The company said it has performed multiple crosses to introgress PM2 into elite breeding lines and run controlled infection and production trials at its Aurora Ridge facility to validate durability and preserve quality traits.
The proprietary marker technology was developed at Aurora Coast with prior UBC collaboration and Genome British Columbia funding; related IP is patent pending in several jurisdictions. Commercialization of PM-resistant cultivars is planned later this year if production trials succeed.
Aurora (NASDAQ: ACB) launched Daily Special, a medical cannabis brand for the German market, available at German pharmacies and via telemedicine from December 19, 2025. The rollout targets affordability and consistent, pharmaceutical‑grade supply backed by global GMP production standards. The initial SKU is a sativa‑dominant Gelonade × Biscotti cultivar with a reported 21–23% THC and <1% CBD, described as citrus, sweet‑earthy and diesel in aroma.
Aurora presents the launch as an expansion of its medical portfolio in Germany, emphasized as one of the company's fastest growing markets, and positions Daily Special to increase patient choice and affordability while leveraging Aurora's global genetic library and production capacity.